{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The primary efficacy endpoint of ORR in patients with AML who received INCB053914 in combination with cytarabine in Part 4 was not assessed because Part 4 was not opened for enrollment owing to this combination regimen not being tolerated in Part 3.","groups":[{"description":"Combination Treatment Group A: INCB053914 50 mg BID + Cytarabine","id":"OG000","title":"Part 4: INCB053914 50 mg BID + Cytarabine)"}],"populationDescription":"Part 4 was not opened for enrollment owing to combination regimen not being tolerated in Part 3.","reportingStatus":"POSTED","timeFrame":"Approximately 2 months","title":"Part 4 Only : Determination of the Efficacy of INCB053914 in Combination With the Intermediate-dose Cytarabine (I DAC) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) Based on Objective Remission Rate (ORR)","type":"PRIMARY"}